BFRI logo

BIOFRONTERA INC

BFRINASDAQ
🏆 #4745 by market capEarnings Nov 11US Equity
$0.89▲ $0.05 (+5.55%)
Market closed · at close
🔔
Track BFRI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.5%
7d▲ 10.1%
14d▲ 4.0%
30d▼ 18.7%
ytd▲ 47.7%
1y▼ 18.7%
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
11.8%
Healthy
📊Gross Margin
84.5%
High
💵FCF Margin
-17.2%
Thin
⚖️P/S Ratio
0.3x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.81 – $0.89
52-Week Range
$0.55 – $1.66
Volume (shares)
141,785
Avg Volume (shares)
—
Shares Outstanding
14.9M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$42M
Last Q Revenue
$12M
P/E Ratio
-1.5
P/S Ratio
0.3x
EPS (TTM)
$-0.49
Dividend Yield
0.00%
Dilution (1yr)
+111.2%
BFRI logo

BIOFRONTERA INC

BFRI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$42M▲ +11.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
78.7%▲ +56.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −46.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +29.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6M▲ +111.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$231K▼ −$752K YoY
StockOtter · stockotter.space

About BIOFRONTERA INC

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·20d ago

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol

Defense World·24d ago

Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast

Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of

GlobeNewsWire·Sep 14

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodyn

Seeking Alpha·Aug 13

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript

Zacks Investment Research·Aug 13

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.

GlobeNewsWire·Aug 13

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy